tbuckley/cabot-search huggingface dataset:
Abstract P1-09-31: Crowdsourcing the collateral damage from breast cancer treatment
Authors: Susan M Love, Amaka Obidegwu, Christine A Fischetti
Journal: Cancer Research (2015)

Abstract INTRODUCTION: Although survivorship research focuses on quality of life after breast cancer treatments, it is usually initiated by providers and focused on previously reported side effects and consequences of treatment. Patients are often reluctant to report side effects they may experience during and after cancer treatment and providers are often reticent to ask. In an effort to explore the patient perspective, the Dr. Susan Love Research Foundation convened a collaboration of advocacy groups to "crowdsource" women’s questions regarding collateral damage from treatment. These concerns will then be incorporated into the Health of Women [HOW] Study, an ongoing, online cohort study of breast cancer open to anyone aged 18 or older. METHODS: Emails to current HOW participants were sent out July 2013 to solicit questions about collateral damage. In October 2013, we undertook the design of a new website landing page for the submission of questions, partnered with other breast cancer advocacy organizations, and began collecting responses. Responses were then categorized to guide questionnaire development. RESULTS: Sixteen breast cancer and other advocacy organizations came together to support this project. Emails to current HOW participants resulted in 1191 responses. The website landing page resulted in an additional 3000 responses. Overall, 16.8% of respondents complained of fatigue, 16.3% of memory problems, 15.7% of anxiety and/or depression, and 14.0% of numbness/neuropathy. Other less frequently reported problems included problems with nail growth, vision, hearing, urinary tract infections, and allergy-like symptoms. CONCLUSION: Through this approach, we received an overwhelming number of responses about collateral damage from treatment. Many of the issues are known side effects, while others are less commonly reported, but debilitating nonetheless. We will next compare responses to previously validated questionnaires, develop a comprehensive collateral damage questionnaire for inclusion in the HOW Study, and generate a report for publication to be distributed to the participants. Citation Format: Susan M Love, Amaka Obidegwu, Christine A Fischetti. Crowdsourcing the collateral damage from breast cancer treatment [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-09-31.
Prevalence of phylogroups and O25/ST131 in susceptible and extended-spectrum β-lactamase-producing Escherichia coli isolates, the Netherlands
Authors: I.T.M.A. Overdevest, A.M.C. Bergmans, J.J. Verweij, J. Vissers, N. Bax, E. Snelders, J.A.J.W. Kluytmans
Journal: Clinical Microbiology and Infection (2015)
Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34+lin- cells, and the generation of colony-forming cell progeny from CD34+lin- cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor
Authors: ID Bernstein, RG Andrews, KM Zsebo
Journal: Blood (1991)
ELN 2013 response status criteria: Relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?
Authors: Gabriel Etienne, Stéphanie Dulucq, Axelle Lascaux, Anna Schmitt, Audrey Bidet, Marie‐Pierre Fort, Eric Lippert, Caroline Bureau, Didier Adiko, Sandrine Hayette, Josy Reiffers, Franck‐Emmanuel Nicolini, François‐Xavier Mahon
Journal: American Journal of Hematology (2014)

The response definitions proposed by the European Leukemia Net (ELN) have been recently modified. We evaluated the new criteria for de novo imatinib (400 mg/d) chronic phase chronic myeloid leukemia (CP-CML) patients. Response status according to the 2009 and 2013 criteria were determined in 180 unselected patients. Outcome of the subgroups of patients were then compared. The 180 patients were classified as optimal responders (OR2009; n = 113, 62.7%), suboptimal responders (SOR2009; n = 47, 26.1%) and failures (FAIL2009; n = 20, 11.1%) according to the 2009 ELN criteria and optimal responders (OR2013; n = 77, 42.7%), warnings (WAR2013; n = 59, 32.7%), and failures (FAIL2013; n = 44, 24.4%) according to the 2013 ELN criteria. No difference in terms of outcome was observed between OR2009 patients who became WAR2013 when compared with OR2013 patients. When compared with FAIL2009 patients, SOR2009 patients who became WAR2013 had better EFS, FFS, PFS, and OS. No difference was observed in PFS or OS in SOR2009 patients who became FAIL2013. The 2013 ELN response status criteria have improved patients classification in terms of response status. However, in our patient population this improvement is related to a better definition of failure rather than that of optimal response for CP-CML patients treated with IM frontline therapy.
Leukocyte adhesion deficiency type 1 (LAD-1)/variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins.
Authors: T W Kuijpers, R A Van Lier, D Hamann, M de Boer, L Y Thung, R S Weening, A J Verhoeven, D Roos
Journal: Journal of Clinical Investigation (1997)

Leukocyte adhesion deficiency (LAD) is characterized by the inability of leukocytes, in particular neutrophilic granulocytes, to emigrate from the bloodstream towards sites of inflammation. Infectious foci are nonpurulent and may eventually become necrotic because of abnormal wound healing. LAD-1 is characterized by the absence of the beta2 integrins (CD11/CD18) on leukocytes. When expression is completely absent, patients often die within the first year. However, low levels of beta2 expression may result in a milder clinical picture of recurrent infection, which offers a better prognosis. In this paper, we describe the in vivo and in vitro findings on a patient with clinical features of a mild LAD-1 disorder, i.e., suffering from bacterial infections without apparent pus formation in the presence of a striking granulocytosis, showing no delayed-type hypersensitivity reaction upon skin testing, no specific antibody generation, but normal in vitro T cell proliferation responses after immunization. Expression levels of CD11/CD18 proteins were completely normal, but leukocyte activation did not result in CD11/ CD18 activation and high-avidity ligand-binding. In vitro chemotaxis and endothelial transmigration of the neutrophils as well as leukocyte aggregation responses were almost absent. On the other hand, beta1 and beta3 integrin-mediated adhesion functions were completely normal. During follow-up, a bleeding tendency related to decreased beta3 activation became clinically apparent, different from previously described cellular adhesion molecule variants. Therefore, this is the first well-documented case of a clinical combined immunodeficiency syndrome that results from nonfunctional CD11/CD18 molecules, and thus designated LAD-1/ variant.
Protecting Resident Performance Evaluations Under Peer Review Immunity Law
Authors: Douglas Beall
Journal: JAMA (1998)

All 50 states and the District of Columbia have enacted peer review statutes that provide varying degrees of immunity to those participating in medical peer review activities.These statutes state that the proceedings, findings, and records of peer review committees are protected from discovery and are normally inadmissible as evidence in judicial or administrative proceedings.The fundamental reason for preserving the confidentiality of these proceedings is to ensure a high quality of peer review activity leading to high-quality patient care.Unfortunately, residents' performance evaluations and related documents are not always similarly protected.These documents can only be adequately protected if they are specifically mentioned in a state's statute governing peer review protections.This lack of protection was proved in a recent medical liability case in Illinois (Thomas v Northwestern Memorial Hospital; No 94, L 7842).In this case a patient claimed that a resident physician and attending physicians had been negligent in providing medical care.The plaintiff alleged that the physicians had not respondedappropriatelytosignsoffetaldistress during a prolonged period of induced labor.The plaintiff's attorney made a motion to compel the defendants to submit documents that described the resident's prior obstetrical/general medical experience and lists of cases, as well as the resident's performance evaluations and other personnel files concerning performance.The defendants had refused to submit these documents, arguing that resident evaluations, examinations, and personnel files are protected by Illinois Medical Studies Act 735 ILCS 5/8-2101, which was designed to offer peer review immunity.The Circuit Court found no support in case law to uphold the defen-
Abstract 3998: Network-based identification of gene signatures of epithelial-mesenchymal transition in breast cancer
Authors: YANG CONG, Ming Zhan, Stephen T. Wong
Journal: Cancer Research (2014)

Abstract Metastasis is a major cause of death in breast cancer patients. Breast cancer cells at the primary site gain metastatic ability through epithelial-mesenchymal transition (EMT). During the process, cancer cells lose cell-cell adhesion mediated by E-cadherin repression and gain motility and invasive properties to penetrate the basement membrane and enter the bloodstream or lymphatic system in order to travel to distant metastatic sites. To investigate the underlying gene regulation mechanism of EMT, we established an EMT gene regulatory network. We first built and validated an EMT signal pathway by Ingenuity Knowledge Base, a repository of expertly curated biological interactions and functional annotations from literatures. Based on gene profiling data of 590 breast cancer patients from The Cancer Genome Atlas (TCGA) and over 370 breast cancer patients from Gene Expression Omnibus (GEO), we modeled the gene regulation mechanism of each gene and its expression regulators in the EMT signal pathway in a stochastic Markov Chain model. In order to identify biomarkers and to determine the dynamical transition process at molecular level during EMT, it is important to identify the corresponding gene expression patterns of epithelial and mesenchymal cells. Several studies have already demonstrated that stable gene expression patterns correspond to stable cell phenotypes. In this study, we reported a cost-efficient computational algorithm developed to identify these stable gene signatures and validate them with gene expression profiles of human mammary epithelial cells and transduced mesenchymal cells. Citation Format: YANG CONG, Ming Zhan, Stephen T. Wong. Network-based identification of gene signatures of epithelial-mesenchymal transition in breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3998. doi:10.1158/1538-7445.AM2014-3998
Abstract 11295: Sonoreperfusion Therapy for Microvascular Obstruction Using Microbubbles and Low Dose tPa
Authors: Sebastiaan T Roos, Francois T Yu, Xucai Chen, Otto Kamp, Albert C van Rossum, Flordeliza S Villanueva, John J Pacella
Journal: Circulation (2014)

Background: Despite successful epicardial recanalization in acute myocardial infarction, adequate microvascular perfusion often fails due to embolization of thrombotic debris causing microvascular obstruction (MVO). We previously reported that long tone burst high mechanical index ultrasound (US) + microbubbles (MB) restored microvascular perfusion (sonoreperfusion, SRP) in an in vitro flow model using PBS perfusate. We sought to demonstrate SRP efficacy in whole blood perfusate with and without low dose tPa. Methods: The model comprised a 4 mm diameter phantom vessel with a 40 μm pore mesh to simulate a microvascular cross section and upstream pressure reflecting thrombus burden. Bovine whole blood and 2x10 6 /ml lipid MB (~3 μm) infused at 0.75 ml/min simulated microvascular flow. Bovine blood microthrombi were injected onto the mesh until upstream pressure was 30 mmHg. US was delivered for 20 min (1 MHz, 1.5 MPa peak negative pressure, 3 sec pulse interval, 1000-5000 cycles) with and without low dose tPa (2.5 μg/ml) during measurement of upstream pressure to assess SRP efficacy (n = 3-7). Lytic rate (rate of pressure drop in the first 4 min) and lytic index (1/area under pressure-time curve) quantified SRP efficacy. Results: In whole blood, lytic rate was 2.6 ± 1.5 mmHg/min at 1000 cycles US+MB increasing to 7.3 ± 3.2 mmHg/min at 5000 cycles US+MB (p&lt;0.01) without tPa. The lytic index was similar for tPa only (2.0 ± 0.5) x 10 -3 mmHg -1 .min -1 and 5000 cycles US + MB without tPa (2.3 ± 0.5) x 10 -3 mmHg -1 .min -1 (p=0.5) but increased to (3.6 ± 0.8) x 10 -3 mmHg -1 .min -1 (p&lt;0.01) for 5000 cycles US+MB+tPa, indicating an additive effect of tPa with US + MB therapy (Fig 1). Conclusions: In whole blood, US + MB therapy restored microvascular perfusion. Similarly to our previous findings with PBS perfusate, SRP efficacy varied with cycle length in the presence of MB. The addition of tPa increased SRP efficacy in blood, suggesting a potential additive effect of low dose tPa and US + MB therapy in vivo .
Mosaic Deficiency in Mitochondrial Oxidative Metabolism Promotes Cardiac Arrhythmia during Aging
Authors: Olivier R. Baris, Stefan Ederer, Johannes F.G. Neuhaus, Jürgen-Christoph von Kleist-Retzow, Claudia M. Wunderlich, Martin Pal, F. Thomas Wunderlich, Viktoriya Peeva, Gabor Zsurka, Wolfram S. Kunz, Tilman Hickethier, Alexander C. Bunck, Florian Stöckigt, Jan W. Schrickel, Rudolf J. Wiesner
Journal: Cell Metabolism (2015)
In Vivo Analysis of the Anatomical Relationship of Coronary Sinus to Mitral Annulus and Left Circumflex Coronary Artery Using Cardiac Multidetector Computed Tomography
Authors: Arti J. Choure, Mario J. Garcia, Barbara Hesse, Matthew Sevensma, George Maly, Neil L. Greenberg, Lynn Borzi, Stephen Ellis, E. Murat Tuzcu, Samir R. Kapadia
Journal: Journal of the American College of Cardiology (2006)
Abstract 16456: Cardiac Troponin Levels Do Not Change in Response to Exercise Stress Testing
Authors: Alex Limkakeng, Weiying Drake, Yuliya Lokhnygina, L. Kristin Newby
Journal: Circulation (2014)

Introduction: Exercise stress testing is commonly used to evaluate chest pain patients in the emergency department (ED). However, sensitivity is suboptimal, and the imaging component is both resource-intensive and may result in radiation exposure. A biomarker-based evaluation component for an exercise stress test would have several advantages.

Hypothesis: We hypothesized that high-sensitivity troponin T (hsTnT) would increase from pre-exercise to post-exercise among patients undergoing exercise stress testing. We further hypothesized that these “stress-delta” values could differentiate patients with myocardial ischemia from those without.

Methods: We prospectively collected demographic and clinical data, including stress test results, from 186 patients who presented to the ED with symptoms of acute coronary syndrome, had ruled out for myocardial infarction by serial contemporary TnT assays and electrocardiography, and were scheduled for exercise echocardiography. Plasma HsTnT (Roche Diagnostics) concentrations were determined at baseline (pre-exercise test) and 2 hours post-stress test. Absolute and relative changes between baseline and post-stress hsTnT values were calculated for patients with and without evidence of myocardial ischemia. All stress tests were interpreted by board-certified cardiologists blinded to stress-delta hsTNT results.

Results: The median age of participants was 50 years, 45.2% were men and 41.4% were African American. Eleven patients (5.9%) had myocardial ischemia on stress echocardiography. The median baseline, 2-hour, and absolute and relative stress delta hsTnT values are shown in Table 1.

Conclusions: There was no evidence of change in hsTnT values in response to exercise stress testing, regardless of the presence of myocardial ischemia by echocardiographic imaging. Future research should determine if stress-delta values of other biomarkers can identify myocardial ischemia.

   ![][1]  [1]: /embed/graphic-1.gif
The Effectiveness of Early Treatment with “Second-Line” Antirheumatic Drugs
Authors: A van der Heide, J W Jacobs, J W Bijlsma, A H Heurkens, C van Booma-Frankfort, M J van der Veen, H C Haanen, D M Hofman, G A van Albada-Kuipers, E J ter Borg, H L Brus, H J Dinant, A A Kruize, Y Schenk
Journal: Annals of Internal Medicine (1996)

To compare two therapeutic strategies for patients with recent-onset rheumatoid arthritis.Open, randomized clinical trial.Outpatient clinics of six clinical centers.238 consecutive patients with recently diagnosed rheumatoid arthritis.Delayed or immediate introduction of treatment with slow-acting antirheumatic drugs (SAARDs).Primary end points were functional disability, pain, joint score, and erythrocyte sedimentation rate at 6 and 12 months and progression of radiologic abnormalities at 12 months.Statistically significant advantages at 12 months for patients receiving the SAARD strategy (immediate treatment with SAARDs) with regard to all primary end points that may be clinically important are indicated by the differences in improvements from baseline and their 95% CIs. These differences were 0.3 (95% CI, 0.2 to 0.6) for disability (range, 0 to 3), 10 mm (CI, 1 to 19 mm) for pain (range, 0 to 100 mm), 39 (CI, 4 to 74) for joint score (range, 0 to 534), and 11 mm/h (CI, 3 to 19 mm/h) for erythrocyte sedimentation rate (range, 1 to 140 mm/h), all in favor of SAARD treatment. The SAARD strategy also appears to be advantageous at 6 months. Radiologic abnormalities progressed at an equal rate in the SAARD and the non-SAARD groups; the difference in progression (range, 0 to 448) was 1 (CI, -3 to 5). Analyses were based on the intention-to-treat principle and thus included 29% of patients in the non-SAARD group who discontinued the non-SAARD treatment strategy; treatment was usually discontinued because of insufficient effectiveness. The SAARD strategy including two alternative SAARDs could not be continued by 8% of patients, usually because of adverse reactions.Early introduction of SAARDs may be more beneficial than delayed introduction for patients with recently diagnosed rheumatoid arthritis.
Biometric Findings on Cardiac Neurosis
Authors: P. Hahn, H. Mayer, Brigitte Stanek
Journal: Psychotherapy and Psychosomatics (1973)

On the basis of Richter’s definition of cardiac neurosis, 32 patients were examined using standardized tests in psychology, biometrics and psychoanalysis. Objective, psychological findings were made with the help of a list of complaints (Zenz), the MMPI (Saarbrücken) and the FPI, Form A (Fahrenberg). The group of patients examined, stemmed from the psychotherapeutic outpatient clinics of both institutions. The patients showed the same findings in the list of complaints and the MMPI as described by Richter and Beckmann. Moreover, the difference between type A and type B could be established with the help of two additional questions in the list of complaints. Types A and B were also distinctly different in the FPI. However, type A patients appeared to be nosologically and clinically more homogeneous than the type B group. When the above results were compared with those of an unselected group of patients from a cardiological outpatient clinic (Schüffel), there were no typical cardiac neurotic profiles, although they must be called cardiac neurotics according to Richter’s definition. The average values of these patients lie below those of a selecte psychosomatic group with other complaints. The authors interpret these results with the selection of the group of patients, and they advocate dividing subgroups from each other within the framework of the collective diagnosis of cardiac neurosis.
Merkel cell carcinoma in Western Australia: a population-based study of incidence and survival
Authors: J. Girschik, K. Thorn, T.W. Beer, P.J. Heenan, L. Fritschi
Journal: British Journal of Dermatology (2011)

Summary Background Merkel cell carcinoma (MCC) is an uncommon but aggressive cutaneous skin cancer. Even with the appropriate treatment, MCC is prone to recurrence, and metastases are common. Exposure to ultraviolet radiation has been suggested as contributing towards the development of MCC. MCC has not been extensively investigated in Australia, even though Australia has the highest incidence of sun-related cancers in the world. Objectives To describe the demographics and determine trends of incidence and survival of MCC cases in Western Australia (WA). Methods All reported invasive cases of MCC incident between 1 January 1993 and 31 December 2007 were extracted from the WA Cancer Registry. Age-adjusted incidence rates for MCC were calculated using direct standardization to the U.S. standard 2000 population. Cause-specific survival was investigated using Kaplan–Meier and Cox proportional hazards analysis. Results Two hundred and fifteen cases were confirmed by pathological review as being definite cases of MCC. Patients were mainly males (65%) and elderly (median age 77 years). Standardized age-adjusted incidence rates were higher in men (1·0/100 000) than in women (0·63/100 000) and higher in older ages (15·5/100 000 in the 85+ year age group) than younger ages (0·1/100 000 in the 30–34 year age group). Five-year cause-specific survival was 64%. Conclusions Incidence of MCC in WA is the highest reported in the literature. In addition, MCC has worse survival than melanoma. The high rates and demographic and anatomical distribution are consistent with sun exposure playing a causal role.
A Boy Eating Porridge
Authors: M. Therese Southgate
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
Authors: Maarten Simoons, Eric Topol, Robert Califf, Frans van de Werf, Paul Armstrong, Philip Edmund Aylward, G.I. Barbash, Eric Bates, A. Betriu, James Chesebro, Jacques Col, David de Bono, Joel Gore, Alan Guerci, John Hampton
Journal: New England Journal of Medicine (1993)

The relative efficacy of streptokinase and tissue plasminogen activator and the roles of intravenous as compared with subcutaneous heparin as adjunctive therapy in acute myocardial infarction are unresolved questions. The current trial was designed to compare new, aggressive thrombolytic strategies with standard thrombolytic regimens in the treatment of acute myocardial infarction. Our hypothesis was that newer thrombolytic strategies that produce earlier and sustained reperfusion would improve survival.